Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, pTPS483-TPS483, 1p
- Subject
- Language
- ISSN
- 0732183X